Activation and differentiation of endogenous neural stem cell progeny in the rat Parkinson animal model.
Daadi
Marcel M
MM
Layton BioScience, Inc., Sunnyvale, CA, USA.
D000818:Animals; D002454:Cell Differentiation / Q000187:drug effects* / Q000502:physiology; D004195:Disease Models, Animal; D004298:Dopamine / Q000096:biosynthesis; D004805:Ependyma / Q000166:cytology / Q000187:drug effects / Q000378:metabolism; D004815:Epidermal Growth Factor / Q000494:pharmacology; D005260:Female; D016222:Fibroblast Growth Factor 2 / Q000494:pharmacology; D006133:Growth Substances / Q000494:pharmacology*; D015918:Infusion Pumps, Implantable; D007276:Injections, Intraventricular; D020547:Lateral Ventricles / Q000166:cytology / Q000187:drug effects / Q000378:metabolism; D017072:Neostriatum / Q000166:cytology / Q000187:drug effects / Q000254:growth & development; D009416:Nerve Regeneration / Q000187:drug effects* / Q000502:physiology; D009474:Neurons / Q000166:cytology / Q000187:drug effects* / Q000378:metabolism; D016627:Oxidopamine / Q000494:pharmacology; D020734:Parkinsonian Disorders / Q000188:drug therapy*; D051381:Rats; D017207:Rats, Sprague-Dawley; D020127:Recovery of Function / Q000187:drug effects* / Q000502:physiology; D013234:Stem Cells / Q000166:cytology / Q000187:drug effects* / Q000378:metabolism; D014446:Tyrosine 3-Monooxygenase / Q000378:metabolism
D006133:Growth Substances; D016222:Fibroblast Growth Factor 2; D004815:Epidermal Growth Factor; D016627:Oxidopamine; D014446:Tyrosine 3-Monooxygenase; D004298:Dopamine